Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?

References

• Mallat Z, Tedgui A. Immunomodulation to combat atherosclerosis: the potential role of immune regulatory cells. Expert Opin. Biol. Ther.4, 1387–1393 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler. Thromb. Vasc. Biol.25, 18–28 (2005).
   PubMed Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature407, 233–241 (2000).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420, 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Colotta F, Borre A, Wang JM et al. Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J. Immunol.148, 760–765 (1992).
   PubMed Web of Science ®Google Scholar
• Wang JM, Sica A, Peri G et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler. Thromb.11, 1166–1174 (1991).
   PubMed Web of Science ®Google Scholar
• Wang DL, Wung BS, Shyy YJ et al. Mechanical strain induces monocyte chemotactic protein-1 gene expression in endothelial cells. Effects of mechanical strain on monocyte adhesion to endothelial cells. Circ. Res.77, 294–302 (1995).
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr. Opin. Lipidol.9, 397–405 (1998).
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med.354, 610–621 (2006).
   PubMed Web of Science ®Google Scholar
• Liao HS, Matsumoto A, Itakura H et al. Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line. Arterioscler. Thromb. Vasc. Biol.19, 1872–1880 (1999).
   PubMedGoogle Scholar
• Hsu HY, Nicholson AC, Hajjar DP. Inhibition of macrophage scavenger receptor activity by tumor necrosis factor-α is transcriptionally and post-transcriptionally regulated. J. Biol. Chem.271, 7767–7773 (1996).
   PubMedGoogle Scholar
• Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S, Hansson GK. Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-γ. Arterioscler. Thromb. Vasc. Biol.15, 1995–2002 (1995).
   PubMedGoogle Scholar
• Janabi M, Yamashita S, Hirano K et al. Oxidized LDL-induced NF-κ B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler. Thromb. Vasc. Biol.20, 1953–1960 (2000).
   PubMed Web of Science ®Google Scholar
• Feng J, Han J, Pearce SF et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-γ. J. Lipid Res.41, 688–696 (2000).
   PubMedGoogle Scholar
• Kume N, Moriwaki H, Kataoka H et al. Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells. Ann. NY Acad. Sci.902, 323–327 (2000).
   PubMed Web of Science ®Google Scholar
• Minami M, Kume N, Kataoka H et al. Transforming growth factor-β(1) increases the expression of lectin-like oxidized low-density lipoprotein receptor-1. Biochem. Biophys. Res. Commun.272, 357–361 (2000).
   PubMed Web of Science ®Google Scholar
• Li PF, Maasch C, Haller H, Dietz R, von Harsdorf R. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation100, 967–973 (1999).
   PubMed Web of Science ®Google Scholar
• Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol.17, 2200–2208 (1997).
   PubMed Web of Science ®Google Scholar
• Chinetti G, Griglio S, Antonucci M et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem.273, 25573–25580 (1998).
   PubMed Web of Science ®Google Scholar
• Lee YW, Kuhn H, Hennig B, Toborek M. IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett.485, 122–126 (2000).
   PubMedGoogle Scholar
• Lindner H, Holler E, Ertl B et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood89, 1931–1938 (1997).
   PubMed Web of Science ®Google Scholar
• Oshima K, Sen L, Cui G et al. Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, and prolongs survival of cardiac allograft. Transplantation73, 1019–1026 (2002).
   PubMedGoogle Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev.79, 1283–1316 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Jonasson L, Holm J, Clowes MM, Clowes AW. γ-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ. Res.63, 712–719 (1988).
   PubMed Web of Science ®Google Scholar
• Harrop AR, Ghahary A, Scott PG, Forsyth N, Uji-Friedland A, Tredget EE. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scar fibroblasts in vitro by interferon-γ. J. Surg. Res.58, 471–477 (1995).
   PubMedGoogle Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res.90, 251–262 (2002).
   PubMed Web of Science ®Google Scholar
• Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb.11, 1223–1230 (1991).
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Mach F, Sukhova GK et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res.81, 448–454 (1997).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. NY Acad. Sci.748, 501–507 (1995).
   PubMed Web of Science ®Google Scholar
• Galis ZS, Muszynski M, Sukhova GK et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res.75, 181–189 (1994).
   PubMed Web of Science ®Google Scholar
• Taubman MB, Fallon JT, Schecter AD et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost.78, 200–204 (1997).
   PubMed Web of Science ®Google Scholar
• Taubman MB. Tissue factor regulation in vascular smooth muscle: a summary of studies performed using in vivo and in vitro models. Am. J. Cardiol.72, 55C–60C (1993).
   Google Scholar
• Osnes LT, Westvik AB, Joo GB, Okkenhaug C, Kierulf P. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine8, 822–827 (1996).
   PubMed Web of Science ®Google Scholar
• Wojta J, Gallicchio M, Zoellner H et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb. Haemost.70, 469–474 (1993).
   PubMedGoogle Scholar
• Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J. Immunol.157, 2610–2617 (1996).
   PubMedGoogle Scholar
• Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol. Lett.45, 61–65 (1995).
   PubMedGoogle Scholar
• Van Der Meeren A, Squiban C, Gourmelon P, Lafont H, Gaugler MH. Differential regulation by IL-4 and IL-10 of radiation-induced IL-6 and IL-8 production and ICAM-1 expression by human endothelial cells. Cytokine11, 831–838 (1999).
   PubMed Web of Science ®Google Scholar
• Mostafa Mtairag E, Chollet-Martin S, Oudghiri M et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc. Res.49, 882–890 (2001).
   PubMedGoogle Scholar
• Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest.90, 382–388 (1992).
   PubMed Web of Science ®Google Scholar
• Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the rennin–angiotensin system. Arterioscler. Thromb. Vasc. Biol.22, 1257–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol.12, 635–673 (1994).
   PubMed Web of Science ®Google Scholar
• Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis145, 33–43 (1999).
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation113, e72–e75 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation113, e152–e155 (2006).
   PubMedGoogle Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Schmeisser A, Soehnlein O, Illmer T et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-κB activity and AT1 receptor expression. Biochem. Biophys. Res. Commun.325, 532–540 (2004).
   PubMedGoogle Scholar
• da Cunha V, Tham DM, Martin-McNulty B et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis178, 9–17 (2005).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Bunte C, Witte J et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J. Am. Coll. Cardiol.44, 362–368 (2004).
   PubMed Web of Science ®Google Scholar
• Lutgens E, Daemen M. HMG-coA reductase inhibitors: lipid-lowering and beyond. Drug Discovery Today1, 189–194 (2004).
   Google Scholar
• Kleemann R, Princen HM, Emeis JJ et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for anti-inflammatory effects of rosuvastatin. Circulation108, 1368–1374 (2003).
   PubMed Web of Science ®Google Scholar
• Sparrow CP, Burton CA, Hernandez M et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol.21, 115–121 (2001).
   PubMed Web of Science ®Google Scholar
• Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler. Thromb. Vasc. Biol.22, 1832–1837 (2002).
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Libby P, Rabkin E et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation103, 993–999 (2001).
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation103, 926–933 (2001).
   PubMed Web of Science ®Google Scholar
• Molloy KJ, Thompson MM, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. Am. J. Cardiol.94, 144–146 (2004).
   PubMed Web of Science ®Google Scholar
• Verhoeven BA, Moll FL, Koekkoek JA et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke37, 2054–2060 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol.46, 1855–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Steffens S, Mach F. Drug insight: immunomodulatory effects of statins – potential benefits for renal patients? Nat. Clin. Pract. Nephrol.2, 378–387 (2006).
   PubMedGoogle Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol.282, 2340–2346 (1999).
   Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353, 2373–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature391, 591–594 (1998).
   PubMed Web of Science ®Google Scholar
• Massberg S, Brand K, Gruner S et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med.196, 887–896 (2002).
   PubMed Web of Science ®Google Scholar
• Massberg S, Vogt F, Dickfeld T, Brand K, Page S, Gawaz M. Activated platelets trigger an inflammatory response and enhance migration of aortic smooth muscle cells. Thromb. Res.110, 187–194 (2003).
   PubMedGoogle Scholar
• Huo Y, Schober A, Forlow SB et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat. Med.9, 61–67 (2003).
   PubMed Web of Science ®Google Scholar
• Cyrus T, Yao Y, Tung LX, Pratico D. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. Atherosclerosis184, 8–14 (2006).
   PubMedGoogle Scholar
• Tous M, Ferre N, Vilella E, Riu F, Camps J, Joven J. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin. Pharmacol. Toxicol.95, 15–19 (2004).
   PubMedGoogle Scholar
• Paul A, Calleja L, Camps J et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci.68, 457–465 (2000).
   PubMed Web of Science ®Google Scholar
• Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation106, 1282–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl Acad. Sci. USA98, 3358–3363 (2001).
   PubMed Web of Science ®Google Scholar
• Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation108, 3017–3023 (2003).
   PubMed Web of Science ®Google Scholar
• Stoller DK, Grorud CB, Michalek V, Buchwald H. Reduction of atherosclerosis with nonsteroidal anti-inflammatory drugs. J. Surg. Res.54, 7–11 (1993).
   PubMedGoogle Scholar
• Dhawan V, Ganguly NK, Majumdar S, Chakravarti RN. Effect of indomethacin on serum lipids, lipoproteins, prostaglandins and the extent and severity of atherosclerosis in rhesus monkeys. Can. J. Cardiol.8, 306–312 (1992).
   PubMedGoogle Scholar
• Egan KM, Wang M, Fries S et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation111, 334–342 (2005).
   PubMed Web of Science ®Google Scholar
• Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol.20, 1724–1728 (2000).
   PubMed Web of Science ®Google Scholar
• Pratico D, Cheng Y, FitzGerald GA. TP or not TP: primary mediators in a close runoff? Arterioscler. Thromb. Vasc. Biol.20, 1695–1698 (2000).
   PubMedGoogle Scholar
• Rogowski O, Shapira I, Assayag EB et al. Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagul. Fibrinolysis17, 19–22 (2006).
   PubMed Web of Science ®Google Scholar
• Olesen M, Kwong E, Meztli A et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc. J.36, 362–367 (2002).
   PubMed Web of Science ®Google Scholar
• Burleigh ME, Babaev VR, Yancey PG et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J. Mol. Cell. Cardiol.39, 443–452 (2005).
   PubMed Web of Science ®Google Scholar
• Rott D, Zhu J, Burnett MS et al. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol.41, 1812–1819 (2003).
   PubMed Web of Science ®Google Scholar
• Burleigh ME, Babaev VR, Patel MB et al. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem. Pharmacol.70, 334–342 (2005).
   PubMed Web of Science ®Google Scholar
• Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation105, 1816–1823 (2002).
   PubMed Web of Science ®Google Scholar
• Bea F, Blessing E, Bennett BJ et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc. Res.60, 198–204 (2003).
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA286, 954–959 (2001).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation104, 2280–2288 (2001).
   PubMed Web of Science ®Google Scholar
• Bolten WW. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis.65, 7–13 (2006).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br. Med. J.332, 1302–1308 (2006).
   PubMed Web of Science ®Google Scholar
• Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk – where are we now? Nat. Clin. Pract. Cardiovasc. Med.2, 290–300 (2005).
   PubMedGoogle Scholar
• Title LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. Coll. Cardiol.42, 1747–1753 (2003).
   PubMed Web of Science ®Google Scholar
• Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem.38, 645–659 (2003).
   PubMed Web of Science ®Google Scholar
• Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol.89, 18D–25D (2002).
   PubMedGoogle Scholar
• Huang ZH, Bates EJ, Ferrante JV et al. Inhibition of stimulus-induced endothelial cell intercellular adhesion molecule-1, E-selectin, and vascular cellular adhesion molecule-1 expression by arachidonic acid and its hydroxy and hydroperoxy derivatives. Circ. Res.80, 149–158 (1997).
   PubMedGoogle Scholar
• Zuccollo A, Shi C, Mastroianni R et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation112, 3001–3008 (2005).
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Fuster V, Corti R et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition – a magnetic resonance imaging study. Eur. Heart J.26, 1557–1561 (2005).
   PubMed Web of Science ®Google Scholar
• Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol.41, 1198–1204 (2003).
   PubMed Web of Science ®Google Scholar
• Ulbrich H, Soehnlein O, Xie X et al. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Biochem. Pharmacol.70, 30–36 (2005).
   PubMedGoogle Scholar
• Alvaro-Gracia JM. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxf.)43(Suppl. 1), i21–i25 (2004).
   PubMed Web of Science ®Google Scholar
• Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation87, 1873–1879 (1993).
   PubMedGoogle Scholar
• Mirshafiey A, Matsuo H, Nakane S, Rehm BH, Koh CS, Miyoshi S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol. Immunotoxicol.27, 255–265 (2005).
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Cuzzocrea S, Rehm B, Mazzon E, Saadat F, Sotoude M. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand. J. Immunol.61, 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc. Res.69, 341–347 (2006).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation80, S181–190 (2005).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation80, S235–S243 (2005).
   PubMed Web of Science ®Google Scholar
• Pethig K, Heublein B, Wahlers T, Dannenberg O, Oppelt P, Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J. Heart Lung Transplant.23, 61–66 (2004).
   PubMedGoogle Scholar
• Romero F, Rodriguez-Iturbe B, Pons H et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis152, 127–133 (2000).
   PubMed Web of Science ®Google Scholar
• Greenstein SM, Sun S, Calderon TM et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J. Surg. Res.91, 123–129 (2000).
   PubMedGoogle Scholar
• Schreiber TC, Greenstein SM, Kim DY et al. Effect of mycophenolate mofetil on atherosclerosis in a rabbit model: initial histologic and immunohistochemical analyses. Transplant. Proc.30, 961–962 (1998).
   PubMedGoogle Scholar
• Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol.56, 47–60 (2005).
   PubMed Web of Science ®Google Scholar
• Lindenfeld J, Miller GG, Shakar SF et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation110, 3858–3865 (2004).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N. Engl. J. Med.354, 483–495 (2006).
   PubMed Web of Science ®Google Scholar
• Mancini D, Pinney S, Burkhoff D et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation108, 48–53 (2003).
   PubMed Web of Science ®Google Scholar
• Waksman R, Pakala R, Burnett MS et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc. Radiat. Med.4, 34–38 (2003).
   PubMedGoogle Scholar
• Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant. Proc.37, 1880–1884 (2005).
   PubMedGoogle Scholar
• Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J. Cardiovasc. Pharmacol.46, 481–486 (2005).
   PubMed Web of Science ®Google Scholar
• Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis172, 31–38 (2004).
   PubMed Web of Science ®Google Scholar
• Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apoE-deficient mice. Am. J. Transplant.3, 562–569 (2003).
   PubMed Web of Science ®Google Scholar
• Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant. Proc.35, 3136–3138 (2003).
   PubMed Web of Science ®Google Scholar
• Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation106, 2379–2384 (2002).
   PubMed Web of Science ®Google Scholar
• Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J. Biochem. (Tokyo)131, 1–15 (2002).
   PubMedGoogle Scholar
• Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J. Cell. Biol.156, 771–774 (2002).
   PubMed Web of Science ®Google Scholar
• Pinney SP, Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr. Opin. Cardiol.19, 170–176 (2004).
   PubMedGoogle Scholar
• Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am. J. Transplant.2, 807–818 (2002).
   PubMed Web of Science ®Google Scholar
• Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Pathol.142, 1906–1915 (1993).
   PubMed Web of Science ®Google Scholar
• Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis116, 181–189 (1995).
   PubMedGoogle Scholar
• Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J. Clin. Invest.96, 1389–1394 (1995).
   PubMedGoogle Scholar
• Andersen HO, Hansen BF, Holm P, Stender S, Nordestgaard BG. Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation. Arterioscler. Thromb. Vasc. Biol.19, 1687–1694 (1999).
   PubMedGoogle Scholar
• Andersen HO, Holm P, Stender S, Hansen BF, Nordestgaard BG. Dose-dependent suppression of transplant arteriosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine. Arterioscler. Thromb. Vasc. Biol.17, 2515–2523 (1997).
   PubMedGoogle Scholar
• Matsumoto T, Saito E, Watanabe H et al. Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. Atherosclerosis139, 95–106 (1998).
   PubMed Web of Science ®Google Scholar
• Wu GD, Cramer DV, Chapman FA et al. FK 506 inhibits the development of transplant arteriosclerosis. Transplant. Proc.23, 3272–3274 (1991).
   PubMed Web of Science ®Google Scholar
• Donners MM, Bot I, De Windt LJ et al. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. Am. J. Transplant.5, 1204–1215 (2005).
   PubMedGoogle Scholar
• Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation63, 977–983 (1997).
   PubMed Web of Science ®Google Scholar
• Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation70, 327–335 (2000).
   PubMedGoogle Scholar
• Zohlnhofer D, Klein CA, Richter T et al. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation103, 1396–1402 (2001).
   PubMed Web of Science ®Google Scholar
• Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic plaques: is it worth the effort? Arterioscler. Thromb. Vasc. Biol.24, 1775–1782 (2004).
   PubMed Web of Science ®Google Scholar
• Mauriello A, Sangiorgi G, Fratoni S et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J. Am. Coll. Cardiol.45, 1585–1593 (2005).
   PubMed Web of Science ®Google Scholar
• Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med.347, 5–12 (2002).
   PubMed Web of Science ®Google Scholar
• Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, Andre-Fouet X. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound. Circulation110, 2875–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant.6, 262–274 (2006).
   PubMed Web of Science ®Google Scholar